Loading…
Citius Pharmaceuticals, Inc. is projected to rise to $0.6053 by 2027, a +4% move from its current price of $0.5827. CTXR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.56 | $0.583 | $0.607 | +0.06% |
| Jul 14 | $0.551 | $0.5834 | $0.6176 | +0.11% |
| Jul 15 | $0.5443 | $0.5837 | $0.6259 | +0.17% |
| Jul 16 | $0.5388 | $0.584 | $0.6331 | +0.23% |
| Jul 17 | $0.534 | $0.5844 | $0.6395 | +0.29% |
| Jul 18 | $0.5297 | $0.5847 | $0.6454 | +0.34% |
| Jul 19 | $0.5258 | $0.585 | $0.6509 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5258 | $0.585 | $0.6509 | +0.40% |
| Week 2 | $0.5051 | $0.5874 | $0.6831 | +0.80% |
| Week 3 | $0.4902 | $0.5897 | $0.7095 | +1.21% |
| Week 4 | $0.4783 | $0.5921 | $0.733 | +1.61% |
| Week 5 | $0.4682 | $0.5945 | $0.7547 | +2.02% |
| Week 6 | $0.4595 | $0.5969 | $0.7752 | +2.43% |
| Week 7 | $0.4518 | $0.5993 | $0.7948 | +2.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
The company’s late-stage pipeline includes Mino-Lok, Halo-Lido, and NoveCite. Citius was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc. trades as CTXR and operates in the Healthcare sector. The stock is currently priced at $0.5573 with a market capitalization of $15.3M and is ranked 4992 by market size.
The current price, market position, and the near-term price trajectory set a challenging but potentially constructive backdrop for investors with selective risk tolerance.
The 2026 forecast places CTXR at an average price of $0.5573, within a range of $0.527 to $0.7672, with an indicated ROI of 0% and NEUTRAL sentiment. This suggests a flat near-term outlook around the current level, with potential for volatility within the stated bounds.
Looking further out, the forecast shifts to a bullish stance beginning in 2032, with 2032 average $0.6977 and a max of $1.19 (ROI 25.2%). The subsequent years show continued upside, with 2033 average $0.7058 and max $1.23 (ROI 26.6%), 2034 average $0.6816 and max $1.21 (ROI 22.3%), and 2035 average $0.6947 and max $1.26 (ROI 24.6%). The long-range view culminates in 2040 with average $0.9424 and max $1.86 (ROI 69.1%), and 2050 with average $1.40 and max $3.09 (ROI 150.7%).
A major floor 18.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 65.1% above — clearing it would confirm fresh momentum.
Key CTXR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTXR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5786 | Buy | $0.5759 | Buy |
| MA 10 | $0.5801 | Buy | $0.5759 | Buy |
| MA 20 | $0.5663 | Buy | $0.5789 | Buy |
| MA 50 | $0.6078 | Sell | $0.6209 | Sell |
| MA 100 | $0.7041 | Sell | $0.7092 | Sell |
| MA 200 | $0.912 | Sell | $1.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.43 | Neutral |
| Stoch RSI (14) | 69.43 | Neutral |
| CCI (20) | 57.99 | Neutral |
| Williams %R (14) | -37.68 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.11 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 62.32 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 46.63 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 0.56 | Buy |
| ADX (14) | 10.95 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is NEUTRAL, with RSI(14) at 40. Price action is below the SMA50 of $0.6118 and well below the SMA200 of $0.918, suggesting limited upside momentum in the immediate term. Support is identified at $0.54 and resistance at $0.697, framing a modest range around the current level.
The 30-day range spans $0.4233 to $0.7337, indicating substantial intraday volatility within a relatively narrow price band. Annualized volatility stands around 80%, underscoring elevated swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.527 | $0.5827 | $0.7958 | 0% | Neutral | |
| $0.4605 | $0.6053 | $0.8533 | +4% | Neutral | |
| $0.3688 | $0.5063 | $0.7511 | -13% | Neutral | |
| $0.3883 | $0.5529 | $0.8533 | -5% | Neutral | |
| $0.3698 | $0.5441 | $0.8678 | -7% | Neutral | |
| $0.3617 | $0.5484 | $0.90 | -6% | Neutral | |
| $0.4706 | $0.7341 | $1.24 | +26% | Bullish | |
| $0.4645 | $0.7444 | $1.28 | +28% | Bullish | |
| $0.4377 | $0.7198 | $1.27 | +24% | Bullish | |
| $0.4351 | $0.7336 | $1.32 | +26% | Bullish | |
| $0.5257 | $0.9961 | $1.93 | +71% | Bullish | |
| $0.6729 | $1.50 | $3.26 | +157% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.527 | $0.5827 | $0.692 | +0.00% |
| August 2026 | $0.4947 | $0.5916 | $0.7321 | +1.53% |
| September 2026 | $0.508 | $0.6139 | $0.7718 | +3.76% |
| October 2026 | $0.4923 | $0.6003 | $0.7649 | -2.21% |
| November 2026 | $0.4826 | $0.5931 | $0.7642 | -1.20% |
| December 2026 | $0.4939 | $0.6113 | $0.7958 | +3.07% |
Click any year to see its month-by-month CTXR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Citius Pharmaceuticals, Inc.'s 2026 outlook centres on $0.5827, within a $0.527 to $0.7958 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CTXR could reach as high as $0.8533, with a base case around $0.6053 and support toward $0.4605 — roughly +4% from $0.5827. A consolidation phase looks the most probable path here.
Expect CTXR to range from $0.3688 to $0.7511 through 2028. The $0.5063 average target implies a -13% move from current prices. That is -16% versus the projected 2027 average. Price action looks broadly range-bound.
The CTXR price prediction for 2029 points to an average of $0.5529 (low $0.3883, high $0.8533) — a potential decline of -5% on today's $0.5827. A consolidation phase looks the most probable path here.
In 2030, CTXR is projected to trade between $0.3698 and $0.8678, averaging $0.5441 — a potential decline of -7% from today's $0.5827. That is -2% versus the projected 2029 average. Price action looks broadly range-bound.
Citius Pharmaceuticals, Inc.'s 2031 outlook centres on $0.5484, within a $0.3617 to $0.90 range. That is up +1% on the projected 2030 average. That marks a -6% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, CTXR could reach as high as $1.24, with a base case around $0.7341 and support toward $0.4706 — roughly +26% from $0.5827. Momentum favours further upside here.
Expect CTXR to range from $0.4645 to $1.28 through 2033. The $0.7444 average target implies a +28% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CTXR price prediction for 2034 points to an average of $0.7198 (low $0.4377, high $1.27) — a potential gain of +24% on today's $0.5827. Momentum favours further upside here.
In 2035, CTXR is projected to trade between $0.4351 and $1.32, averaging $0.7336 — a potential gain of +26% from today's $0.5827. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Citius Pharmaceuticals, Inc.'s 2040 outlook centres on $0.9961, within a $0.5257 to $1.93 range. That is up +36% on the projected 2035 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2050, CTXR could reach as high as $3.26, with a base case around $1.50 and support toward $0.6729 — roughly +157% from $0.5827. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTXR today (≈ 1,716.148962 CTXR) could be worth
$2,566.16
+$1,566.16 (+157%) by 2050 · US Dollar
Based on the average projected CTXR price of $1.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTXRwould be worth at today's price.
$1,000 invested in CTXR on Jul 10, 2025 (≈ 613.496934 CTXR) would be worth
$357.48
-$642.52 (-64.3%) today · 0.36× · US Dollar
Based on a CTXR entry price of $1.63 vs. today's $0.5827.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.575 | $1,013.39 | +1.3% |
| 1 month ago | $0.553 | $1,053.71 | +5.4% |
| 3 months ago | $0.805 | $723.85 | -27.6% |
| 6 months ago | $0.885 | $658.42 | -34.2% |
| 1 year ago | $1.63 | $357.48 | -64.3% |
| All time (5.0y) ago | $49.5 | $11.77 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTXR forecast.
Our base-case forecast reaches $1.20 around 2050.
Implied market cap at $1.20: $32.94M
The multi-year forecast envisions a transition to bullish conditions from 2032 onward, with the average price rising from $0.6977 in 2032 to higher levels in subsequent years. The 2032-2035 window shows averages around the mid-$0.60s to $0.70s and maxes around $1.19-$1.26, delivering ROIs in the mid-teens to mid-20s and bullish sentiment. The forecast then accelerates: 2040’s average $0.9424 and max $1.86 yield a 69.1% upside, and by 2050 the average reaches $1.40 with a max of $3.09, equating to an estimated 150.7% ROI.
These figures imply meaningful upside potential over a longer horizon, tempered by earlier-year downside risks shown in 2028 (-13.6% ROI), 2029 (-5.5%), 2030 (-8%), and 2031 (-7.7%). The outlook should be considered as estimates, not guarantees, with substantial uncertainty and market risk.
Tap a question to reveal the answer.
In 2030, the average forecast price is $0.5127, with a low of $0.3451 and a high of $0.8254; ROI -8% and sentiment NEUTRAL.
The forecast shows a shift to BULLISH sentiment starting in 2032, with 2032 average $0.6977 and max $1.19 (ROI 25.2%), 2033 average $0.7058 and max $1.23 (ROI 26.6%), 2034 average $0.6816 and max $1.21 (ROI 22.3%), and 2035 average $0.6947 and max $1.26 (ROI 24.6%).
Yes. The 2050 forecast maximum is $3.09, with a 2050 average of $1.40 and a minimum of $0.6287; ROI 150.7%.
Current price is $0.5573; market cap is $15.3M; rank 4992.
The 30-day range is $0.4233 to $0.7337, with support at $0.54 and resistance at $0.697.
Citius Pharmaceuticals, Inc. Community Discussion
0Share your Citius Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.